BIOTRON LIMITED — Capital/Financing Update 2014

Nov 4, 2014

==> picture [223 x 34] intentionally omitted <==

Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au

5 November 2014

The Manager Companies ASX Limited 20 Bridge Street SYDNEY NSW 2000

(2 pages by email)

Dear Madam,

FULLY UNDERWRITTEN $4.06 MILLION RIGHTS ISSUE CLOSES OVERSUBSCRIBED

The Board of Biotron Limited is pleased to advise that the rights issue announced on 15 October 2014 closed on 31 October 2014 oversubscribed. All securities offered were applied for under the rights issue and as a consequence there was no shortfall. The fully underwritten issue raised approximately $4.06 million (before costs).

The Company is very pleased with the outcome and the level of support it received from its shareholders. A significant number of shareholders applied for allocations in excess of their entitlement.

The rights issue was priced at 8 cents and for every share applied for, investors received one new option which will be quoted under the ASX code BITO.

The holding statements for the new securities will be dispatched shortly. The rights issue was underwritten and managed by Patersons Securities Limited.

Enquiries

Peter J. Nightingale Company Secretary Biotron Limited +61-2 9300 3344

About Biotron and BIT225

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need, with a major focus on HIV and HCV. The Company has BIT225 in clinical development for both HIV and HCV, and also has several earlier stage preclinical and research programs for several other viral infections including Dengue.

BIT225 has recorded encouraging data against HCV in clinical trials. A phase 2a trial in HCV demonstrated that 100% of HCV genotype 1 infected patients receiving BIT225 (400 mg) in combination with current standard of care therapies interferon and ribavirin had undetectable virus after 48 weeks. A phase 2 trial in HIV/HCV co-infected patients showed that all HCV genotype 3 patients completing 28 days of treatment with

BIT225 in combination with interferon and ribavirin achieved SVR12, with undetectable HCV 12 weeks after completing all therapy.

BIT225 is also in development for treatment of HIV, and is the first in a new class of antiviral drugs that may provide a new approach to eradication of this virus. It has shown clinical efficacy against HIV in reservoir cells, and has the potential to be combined with new or existing anti-retroviral drugs to eradicate long-lived pools of virus that are not eliminated with current treatments.

Yours sincerely

Peter J. Nightingale Company Secretary

pjn7908

2